lazabemide lazabemide lazabemide (proposed trade names pakio, tempium) is a reversible and selective inhibitor of monoamine oxidase b (mao-b) that was under development as an antiparkinsonian agent but was never marketed. lazabemideclinical dataroutes ofadministrationoralatc codenonelegal statuslegal status development terminated identifiers iupac name n-(2-aminoethyl)-5-chloro-pyridine-2-carboxamide cas number103878-84-8pubchem cid71307iuphar/bps6640chemspider64426unii420hd787n9keggd04681comptox dashboard (epa)dtxsid2048294 chemical and physical dataformulac8h10cln3omolar mass199.64 g·mol−1